{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T23:09:38Z","timestamp":1779232178503,"version":"3.51.4"},"reference-count":30,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,3,20]],"date-time":"2026-03-20T00:00:00Z","timestamp":1773964800000},"content-version":"vor","delay-in-days":19,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004331","name":"Johnson and Johnson","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004331","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100023280","name":"Seqirus","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100023280","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","lungcancerjournal.info","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Lung Cancer"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1016\/j.lungcan.2026.109302","type":"journal-article","created":{"date-parts":[[2026,2,2]],"date-time":"2026-02-02T16:30:05Z","timestamp":1770049805000},"page":"109302","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Amivantamab plus chemotherapy versus chemotherapy for first-line treatment of participants with EGFR exon 20 insertion-mutated advanced non-small cell lung cancer: PAPILLON Asia subgroup analysis"],"prefix":"10.1016","volume":"213","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1072-9941","authenticated-orcid":false,"given":"Caicun","family":"Zhou","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ke-Jing","family":"Tang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Baogang","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sang-We","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Satoru","family":"Kitazono","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5705-9423","authenticated-orcid":false,"given":"Akira","family":"Ono","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7717-9406","authenticated-orcid":false,"given":"Muthukkumaran","family":"Thiagarajan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jen-Yu","family":"Hung","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0452-2987","authenticated-orcid":false,"given":"Michael","family":"Boyer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5033-1479","authenticated-orcid":false,"given":"Timu\u00e7in","family":"\u00c7\u0130l","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yu","family":"Yao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rajnish","family":"Nagarkar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John","family":"Xie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Archan","family":"Bhattacharya","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Honeylet","family":"Wortman-Vayn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-4456-8055","authenticated-orcid":false,"given":"Mahadi","family":"Baig","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Trishala","family":"Agrawal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patricia","family":"Lorenzini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Se-Hoon","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5562-270X","authenticated-orcid":false,"given":"Byoung Chul","family":"Cho","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.lungcan.2026.109302_b0005","unstructured":"World Health Organization, International Agency for Research on Cancer. Globoal Cancer Observatory. Globocan 2022. Asia. Available from https:\/\/gco.iarc.who.int\/media\/globocan\/factsheets\/populations\/935-asia-fact-sheet.pdf (accessed 05 November 2024)."},{"key":"10.1016\/j.lungcan.2026.109302_b0010","doi-asserted-by":"crossref","unstructured":"R.A. Soo, T. Reungwetwattana, H.A. Perroud, U. Batra, S. Kilickap, L.F. Tejado Gallegos, N. Donner, M. Alsayed, R. Huggenberger, D. Van Tu, Prevalence of EGFR mutations in patients with resected stages I to III NSCLC: results from the EARLY-EGFR study, J. Thorac. Oncol., 19(10) (2024) 1449-1459. https:\/\/doi.org\/10.1016\/j.jtho.2024.06.008.","DOI":"10.1016\/j.jtho.2024.06.008"},{"issue":"9","key":"10.1016\/j.lungcan.2026.109302_b0015","first-page":"2892","article-title":"EGFR mutation incidence in non-small-cell lung cancer of adenocarcinoma histology: a systematic review and global map by ethnicity (mutMapII)","volume":"5","author":"Midha","year":"2015","journal-title":"Am. J. Cancer Res."},{"issue":"1","key":"10.1016\/j.lungcan.2026.109302_b0020","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1007\/s40291-021-00563-1","article-title":"Worldwide prevalence of epidermal growth factor receptor mutations in non-small cell lung cancer: a meta-analysis","volume":"26","author":"Melosky","year":"2022","journal-title":"Mol. Diagn. Ther."},{"issue":"3","key":"10.1016\/j.lungcan.2026.109302_b0025","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1038\/nrc2088","article-title":"Epidermal growth factor receptor mutations in lung cancer","volume":"7","author":"Sharma","year":"2007","journal-title":"Nat. Rev. Cancer"},{"issue":"3","key":"10.1016\/j.lungcan.2026.109302_b0030","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0247620","article-title":"Epidemiological and clinical burden of EGFR Exon 20 insertion in advanced non-small cell lung cancer: a systematic literature review","volume":"16","author":"Burnett","year":"2021","journal-title":"PLoS One"},{"key":"10.1016\/j.lungcan.2026.109302_b0035","doi-asserted-by":"crossref","DOI":"10.1177\/10732748241292782","article-title":"Targeting EGFR exon 20 Insertion mutations in non-small-cell lung cancer: changes in treatment strategies are coming","volume":"31","author":"Liu","year":"2024","journal-title":"Cancer Control"},{"issue":"2","key":"10.1016\/j.lungcan.2026.109302_b0040","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1097\/JTO.0b013e3182779d18","article-title":"Natural history and molecular characteristics of lung cancers harboring EGFR exon 20 insertions","volume":"8","author":"Oxnard","year":"2013","journal-title":"J. Thorac. Oncol."},{"issue":"5","key":"10.1016\/j.lungcan.2026.109302_b0045","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1038\/s41591-018-0007-9","article-title":"Mechanisms and clinical activity of an EGFR and HER2 exon 20-selective kinase inhibitor in non-small cell lung cancer","volume":"24","author":"Robichaux","year":"2018","journal-title":"Nat. Med."},{"issue":"6","key":"10.1016\/j.lungcan.2026.109302_b0050","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1007\/s40259-022-00556-4","article-title":"Non-small cell lung cancer with EGFR or HER2 Exon 20 insertion mutations: diagnosis and treatment options","volume":"36","author":"Brazel","year":"2022","journal-title":"BioDrugs"},{"issue":"10","key":"10.1016\/j.lungcan.2026.109302_b0055","article-title":"Real-world response and outcomes in patients with NSCLC with EGFR Exon 20 insertion mutations","volume":"4","author":"Ou","year":"2023","journal-title":"JTO Clin. Res. Rep."},{"issue":"3","key":"10.1016\/j.lungcan.2026.109302_b0060","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1007\/s12325-022-02408-7","article-title":"An adjusted treatment comparison comparing amivantamab versus real-world clinical practice in europe and the united states for patients with advanced non-small cell lung cancer with activating epidermal growth factor receptor Exon 20 insertion mutations","volume":"40","author":"Chouaid","year":"2023","journal-title":"Adv. Ther."},{"key":"10.1016\/j.lungcan.2026.109302_b0065","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.lungcan.2021.10.020","article-title":"Comparative clinical outcomes for patients with advanced NSCLC harboring EGFR exon 20 insertion mutations and common EGFR mutations","volume":"162","author":"Bazhenova","year":"2021","journal-title":"Lung Cancer"},{"issue":"25","key":"10.1016\/j.lungcan.2026.109302_b0070","first-page":"00699","article-title":"Overall survival in EGFR-mutant advanced NSCLC treated with first-line osimertinib: a cohort study integrating clinical and biomarker data in the United States","volume":"S1556\u20130864","author":"Sabari","year":"2025","journal-title":"J. Thorac. Oncol."},{"issue":"3","key":"10.1016\/j.lungcan.2026.109302_b0075","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.pccm.2024.08.002","article-title":"Overcoming EGFR-TKI resistance by targeting the tumor microenvironment","volume":"2","author":"Zhang","year":"2024","journal-title":"Chin. Med. J. Pulm. Crit. Care Med."},{"issue":"13","key":"10.1016\/j.lungcan.2026.109302_b0080","doi-asserted-by":"crossref","first-page":"3942","DOI":"10.1158\/0008-5472.CAN-15-2833","article-title":"A novel bispecific antibody targeting EGFR and cMet is effective against EGFR inhibitor-resistant lung tumors","volume":"76","author":"Moores","year":"2016","journal-title":"Cancer Res."},{"issue":"8","key":"10.1016\/j.lungcan.2026.109302_b0085","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.1158\/2159-8290.CD-20-0116","article-title":"Antitumor activity of amivantamab (JNJ-61186372), an EGFR-MET bispecific antibody, in diverse models of EGFR exon 20 insertion-driven NSCLC","volume":"10","author":"Yun","year":"2020","journal-title":"Cancer Discov."},{"issue":"10","key":"10.1016\/j.lungcan.2026.109302_b0090","doi-asserted-by":"crossref","first-page":"2044","DOI":"10.1158\/1535-7163.MCT-20-0071","article-title":"Amivantamab (JNJ-61186372), an Fc enhanced EGFR\/cMet bispecific antibody, induces receptor downmodulation and antitumor activity by monocyte\/macrophage trogocytosis","volume":"19","author":"Vijayaraghavan","year":"2020","journal-title":"Mol. Cancer Ther."},{"issue":"30","key":"10.1016\/j.lungcan.2026.109302_b0095","doi-asserted-by":"crossref","first-page":"3391","DOI":"10.1200\/JCO.21.00662","article-title":"Amivantamab in EGFR exon 20 insertion-mutated non-small-cell lung cancer progressing on platinum chemotherapy: initial results from the CHRYSALIS phase I study","volume":"39","author":"Park","year":"2021","journal-title":"J. Clin. Oncol."},{"issue":"17","key":"10.1016\/j.lungcan.2026.109302_b0100","doi-asserted-by":"crossref","first-page":"3262","DOI":"10.1158\/1078-0432.CCR-22-3713","article-title":"FDA approval summary: amivantamab for the treatment of patients with non-small cell lung cancer with EGFR exon 20 insertion mutations","volume":"29","author":"Chon","year":"2023","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.lungcan.2026.109302_b0105","unstructured":"Euroepan Medicines Agency. Rybrevant amivantamab. Available from https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/rybrevant (accessed 08 Nov 2024)."},{"key":"10.1016\/j.lungcan.2026.109302_b0110","doi-asserted-by":"crossref","unstructured":"C. Zhou, K.J. Tang, B.C. Cho, B. Liu, L. Paz-Ares, S. Cheng, S. Kitazono, M. Thiagarajan, J.W. Goldman, J.K. Sabari, R.E. Sanborn, A.S. Mansfield, J.Y. Hung, M. Boyer, S. Popat, J. Mourao Dias, E. Felip, M. Majem, M. Gumus, S.W. Kim, A. Ono, J. Xie, A. Bhattacharya, T. Agrawal, S.M. Shreeve, R.E. Knoblauch, K. Park, N. Girard, P. Investigators, Amivantamab plus chemotherapy in NSCLC with EGFR exon 20 insertions, N Engl. J. Med., 389(22) (2023) 2039-2051. https:\/\/doi.org\/10.1056\/NEJMoa2306441.","DOI":"10.1056\/NEJMoa2306441"},{"key":"10.1016\/j.lungcan.2026.109302_b0115","unstructured":"EMA recommends extension of indications for amivantamab. 06 May 2024. Available from https:\/\/www.esmo.org\/oncology-news\/ema-recommends-extension-of-indications-for-amivantamab (accessed 08 Nov 2024)."},{"key":"10.1016\/j.lungcan.2026.109302_b0120","unstructured":"FDA approves amivantamab-vmjw for EGFR exon 20 insertion-mutated non-small cell lung cancer indications. Available from https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-amivantamab-vmjw-egfr-exon-20-insertion-mutated-non-small-cell-lung-cancer-indications (accessed 08 Nov 2024)."},{"key":"10.1016\/j.lungcan.2026.109302_b0125","doi-asserted-by":"crossref","first-page":"S1638","DOI":"10.1016\/j.annonc.2024.10.668","article-title":"Crossover-adjusted overall survival for amivantamab plus chemotherapy versus chemotherapy in first-line EGFR exon 20 insertion NSCLCS","volume":"35","author":"Lu","year":"2024","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.lungcan.2026.109302_b0130","doi-asserted-by":"crossref","unstructured":"A. Passaro, J. Wang, Y. Wang, S.H. Lee, B. Melosky, J.Y. Shih, J. Wang, K. Azuma, O. Juan-Vidal, M. Cobo, E. Felip, N. Girard, A.B. Cortot, R. Califano, F. Cappuzzo, S. Owen, S. Popat, J.L. Tan, J. Salinas, P. Tomasini, R.D. Gentzler, W.N. William, Jr., K.L. Reckamp, T. Takahashi, S. Ganguly, D.M. Kowalski, A. Bearz, M. MacKean, P. Barala, A.B. Bourla, A. Girvin, J. Greger, D. Millington, M. Withelder, J. Xie, T. Sun, S. Shah, B. Diorio, R.E. Knoblauch, J.M. Bauml, R.G. Campelo, B.C. Cho, M.-. Investigators, Amivantamab plus chemotherapy with and without lazertinib in EGFR-mutant advanced NSCLC after disease progression on osimertinib: primary results from the phase III MARIPOSA-2 study, Ann. Oncol., 35(1) (2024) 77-90. https:\/\/doi.org\/10.1016\/j.annonc.2023.10.117.","DOI":"10.1016\/j.annonc.2023.10.117"},{"key":"10.1016\/j.lungcan.2026.109302_b0135","doi-asserted-by":"crossref","first-page":"1486","DOI":"10.1056\/NEJMoa2403614","article-title":"Amivantamab plus lazertinib in previously untreated EGFR-mutated advanced NSCLC","volume":"391","author":"Cho","year":"2024","journal-title":"N Engl. J. Med."},{"key":"10.1016\/j.lungcan.2026.109302_b0140","doi-asserted-by":"crossref","DOI":"10.1016\/j.jtho.2025.01.018","article-title":"Preventing infusion-related reactions with intravenous amivantamab-results from SKIPPirr, a phase 2 study: a brief report","author":"Spira","year":"2025","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.lungcan.2026.109302_b0145","doi-asserted-by":"crossref","unstructured":"N.B. Leighl, H. Akamatsu, S.M. Lim, Y. Cheng, A.R. Minchom, M.E. Marmarelis, R.E. Sanborn, J. Chih-Hsin Yang, B. Liu, T. John, B. Massuti, A.I. Spira, S.H. Lee, J. Wang, J. Li, C. Liu, S. Novello, M. Kondo, M. Tamiya, E. Korbenfeld, M. Moskovitz, J.Y. Han, M. Alexander, R. Joshi, E. Felip, P.J. Voon, P. Danchaivijitr, P.C. Hsu, F.J. Silva Melo Cruz, T. Wehler, L. Greillier, E. Teixeira, D. Nguyen, J.K. Sabari, A. Qin, D. Kowalski, M.A.N. Sendur, J. Xie, D. Ghosh, A. Alhadab, N. Haddish-Berhane, P.L. Clemens, P. Lorenzini, R.B. Verheijen, M. Gamil, J.M. Bauml, M. Baig, A. Passaro, P. Investigators, Subcutaneous versus intravenous amivantamab, both in combination with lazertinib, in refractory epidermal growth factor receptor-mutated non-small cell lung cancer: primary results from the phase III PALOMA-3 study, J. Clin. Oncol., 42(30) (2024) 3593-3605. https:\/\/doi.org\/10.1200\/JCO.24.01001.","DOI":"10.1200\/JCO.24.01001"},{"issue":"3","key":"10.1016\/j.lungcan.2026.109302_b0150","doi-asserted-by":"crossref","first-page":"S14","DOI":"10.1016\/S1556-0864(25)00205-9","article-title":"10MO: Preventing moderate to severe dermatologic adverse events in first-line EGFR-mutant advanced NSCLC treated with amivantamab plus lazertinib: early success of the COCOON trial","volume":"20","author":"Girard","year":"2025","journal-title":"J. Thoracic. Oncol."}],"container-title":["Lung Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500226000462?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500226000462?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,20]],"date-time":"2026-03-20T18:04:40Z","timestamp":1774029880000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0169500226000462"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":30,"alternative-id":["S0169500226000462"],"URL":"https:\/\/doi.org\/10.1016\/j.lungcan.2026.109302","relation":{},"ISSN":["0169-5002"],"issn-type":[{"value":"0169-5002","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Amivantamab plus chemotherapy versus chemotherapy for first-line treatment of participants with EGFR exon 20 insertion-mutated advanced non-small cell lung cancer: PAPILLON Asia subgroup analysis","name":"articletitle","label":"Article Title"},{"value":"Lung Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.lungcan.2026.109302","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"109302"}}